The Recursion REC-4881 Phase 2 results arrive at a moment when the AI drug discovery sector is looking for clinical proof, and the company announced them alongside its third-quarter financials on 2 November 2026. REC-4881, an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP), cut total polyp burden in 13 of 15 patients after 12 weeks, with a median reduction of 47%, in a small open-label study. This business analysis looks at what the data mean for Recursion’s pipeline, cash position, partnerships and the case for AI-derived medicines. It is news reporting and not investment advice.
Recursion REC-4881 Phase 2 results: business takeaways
- Clinical: 13 of 15 patients had lower total polyp burden, with a median of 47%; 85% of evaluable patients stayed below baseline 12 weeks after stopping.
- Regulatory: a registrational trial is expected in the second half of 2027, subject to ongoing FDA discussions; the drug has Orphan Drug and Fast Track designations.
- Financial: cash of $561.5 million at 30 September 2026 and, with an October offering, about $748.7 million pro forma, which the company says extends its runway into 2029.
- Partnerships: Sanofi optioned a first development candidate, triggering a $10 million milestone; Genentech exercised its first Validated Target Option.
- Caveat: the study is small, single-arm and open-label, and a second drug, REC-1245, has only early Phase 1 data.
What the Recursion REC-4881 Phase 2 results change for the pipeline
REC-4881 is the most advanced clinical programme the company highlighted. The company describes it as a potential first-in-class therapy for a rare disease it says affects more than 50,000 patients in the US and five large European markets, about 35,000 of them after colectomy, and it puts the potential opportunity at $15 billion. That figure is a company estimate and we have not verified it. It depends on price, uptake, label and reimbursement, none of which exist yet. The study is registered as NCT05552755. The company also says it analysed an external registry in which polyp burden increased over time in similar patients, which it uses as context.
How credible are the Recursion REC-4881 Phase 2 results commercially
For a business reader, the critical step is the registrational path. The company will give more detail later in 2026 and says the FDA may still differ on the endpoint or require extra data. Orphan Drug and Fast Track status, explained on the FDA website, can support development speed and incentives, but they do not guarantee approval. The data also include four Grade 3 treatment-related events among 26 patients (15%) and four discontinuations for lower-grade events, which payers and prescribers will weigh against benefit.
Cash and runway behind the Recursion REC-4881 Phase 2 results
In its third-quarter report, Recursion said revenue was $18.6 million against $5.2 million a year earlier, mostly from the Sanofi milestone. Research and development expense fell to $99.1 million from $121.1 million, and the net loss narrowed to $119.0 million from $162.3 million. By our own calculation, the net loss is about 27% smaller than a year earlier. Cash operating expense guidance is under $375 million for 2026 and under $360 million for 2027. A 16 October offering added about $187.2 million in net proceeds. The company expects its cash to last into 2029 on current plans without further financing, which is its own projection.
Partnership economics in the Recursion REC-4881 Phase 2 results update
Sanofi optioned the first development candidate from an immunology collaboration, a potential first-in-class dual-target oral small molecule that Sanofi will lead, with Phase 1 expected in 2027. Total upfront and milestone payments from Sanofi have reached $144 million, and Recursion is eligible for more than $300 million in further milestones plus double-digit royalties if a product is approved. Genentech exercised its first Validated Target Option in neuroscience, and Recursion says it has received $216 million from the Roche and Genentech collaboration to date. Partner decisions like these are an external check on the platform, though they concern different programmes from REC-4881.
Governance in the Recursion REC-4881 Phase 2 results period
Fred Hassan became Chair of the board on 31 October 2026. He previously led Schering-Plough and Pharmacia and currently holds several board and chair roles in the sector, according to the company. A new chair does not change the data, but it is part of how the company presents its next phase.
REC-1245 and the oncology bet in the Recursion REC-4881 Phase 2 results update
REC-1245 is an investigational oral degrader of the splicing factor RBM39. With a data cut-off of 21 August 2026, the company reported two confirmed partial responses in endometrial cancer and one unconfirmed partial response in liver cancer, all at 45 mg daily or higher, and disease control in 11 of 12 patients at those doses. The company says it identified the molecule within 18 months after screening 204 compounds, which it presents as evidence of platform speed. Early endometrial expansion data are expected in the second half of 2027. These are early findings in small numbers, not evidence of an approved treatment.
What the Recursion REC-4881 Phase 2 results say about AI drug discovery
Recursion says its AI foundation models pointed to MEK1/2 inhibition through phenotypic screening, and its chief executive, Najat Khan, called the data the clearest proof point yet of what the company was built to do. That is the company’s framing. The clinical results show that the molecule has an effect on polyp burden in a small study; they do not isolate the contribution of AI. For sector deals see our report on AstraZeneca’s $40 million upfront AI pact with insitro.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Artificial Intelligence for Drug Discovery Market report values the global segment at USD 2.8 billion in 2025 and projects USD 30.49 billion by 2035, a CAGR of 26.9% for 2026 to 2035. By our own calculation, that is about 10.9 times the 2025 value. North America held 56% in 2025, Asia Pacific is the fastest-growing region at 34.5%, software and AI platforms were 72% of the market, and large pharma and biotech were 54% of organisations. The report has internal inconsistencies, including a venture-capital share that does not match its own totals, so the figures are indicative. It does not size FAP.
Questions investors and partners may ask about the Recursion REC-4881 Phase 2 results
Will the FDA accept polyp burden as an endpoint? What will a registrational trial cost and who will fund it? Will longer treatment show durable benefit and acceptable safety? Can the company repeat this with other programmes? See more in our pharmaceuticals section.
Timeline of the Recursion REC-4881 Phase 2 results
- 15 October 2026: upper digestive tract results announced.
- 16 October 2026: stock offering with about $187.2 million net proceeds.
- 31 October 2026: Fred Hassan becomes Chair.
- 2 November 2026: expanded TUPELO results, REC-1245 data and third-quarter financials.
- Second half of 2027: registrational trial for REC-4881 expected to start.
General background: how small trials move biotech companies
Early clinical data often move a biotech’s outlook, financing options and partnering interest more than they move final approval odds. Small open-label results are best seen as signals that justify the next, larger and costlier trial.
Our analysis of the Recursion REC-4881 Phase 2 results
In our assessment, the Recursion REC-4881 Phase 2 results strengthen the clinical story and the cash position gives time to test it. The commercial value still hinges on a controlled trial, regulatory alignment and long-term safety.
What is not disclosed about the Recursion REC-4881 Phase 2 results
- The registrational endpoint agreed with the FDA.
- The cost and funding plan for the registrational trial.
- Pricing, label or reimbursement expectations.
Risks and caveats
This article relies on the company’s announcement, which includes forward-looking statements. Trials can fail at any stage, and early data may not predict final results. The $15 billion figure and the runway are company estimates. This is not investment advice.
What to watch next
- Registrational trial details later in 2026.
- Further Sanofi and Genentech milestones.
- REC-1245 expansion data in the second half of 2027.
FAQ
What are the main Recursion REC-4881 Phase 2 results?
13 of 15 patients had lower total polyp burden after 12 weeks, with a median reduction of 47%.
How long does Recursion’s cash last?
The company expects into 2029 on current plans, which is its own projection.
Is REC-4881 approved?
No. It is investigational.
How we reported this: we relied on the company’s announcement of 2 November 2026, ClinicalTrials.gov, regulator pages and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 3 November 2026. This is news reporting and not advice.
